We discuss the potential of the ApoE-enriched PC as a targeting strategy for brain delivery, which provides novel insights into glioma therapy and further improves the design of targeted drug delivery systems with high efficiency and enhanced safety for better clinical translation. The gene discussed is APOE; the disease is glioma.